Formulation Development
SGS Announces Expansion of Biopharmaceutical Testing Capabilities
SGS recently announced it has added new capacity and capabilities at its center of excellence in Lincolnshire, IL. This expansion adds new instrumentation and expertise…
Cybrexa Therapeutics Announces First Patient Dosed With First-in-Class Peptide-Drug Conjugate in Phase 2 Trial in Ovarian Cancer
Cybrexa Therapeutics recently announced the first patient has been dosed in a Phase 2 clinical trial evaluating CBX-12 in patients with platinum-resistant or refractory ovarian…
Akoya’s Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
Akoya Biosciences, Inc. recently announced the its PhenoCycler Fusion and PhenoImager HT spatial proteomics platforms will be used to analyze tissue samples as part of…
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
Monopar Therapeutics Inc. recently announced the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu (MNPR-101 conjugated to lutetium-177) is now active and recruiting…
Abivax Announces First Patient Enrolled in Phase 2b Trial of Obefazimod in Crohn’s Disease
Abivax SA recently announced the first patient was enrolled in its Phase 2b ENHANCE-CD (NCT06456593) trial evaluating obefazimod in patients with Crohn’s disease (CD). The…
Biodexa Provides Update on Progression Free & Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
Biodexa Pharmaceuticals PLC recently announced an update in respect of its open label Phase 1 study of MTX110 in recurrent glioblastoma. In October 2023, the…
Recipharm Strengthens Pharmaceutical Development Capabilities With Strategic Investments
Recipharm is expanding its pharmaceutical development capabilities, through targeted investments and the integration of cutting-edge technologies. This investment bolsters its services for early- and late-…
BioDuro-Sundia Launches New Compound Management Center, Strengthening Drug Discovery Services
BioDuro-Sundia recently announced the launch of a new Compound Management Center at its Waigaoqiao site in the Shanghai Free-Trade Zone, China. This new center enables…
Legend Biotech to Establish New, State-of-the-Art Cell Therapy R&D Facility in Philadelphia
Legend Biotech Corporation recently announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, PA, to advance its portfolio of next-generation…
Hovione & Zerion Pharma Create Joint Venture to Further Expand Use of Dispersome Technology
Hovione Farmaciência, S.A. and Zerion Pharma A/S recently announced they have expanded their partnership to accelerate the development of the Dispersome technology platform and further…
First Patient Dosed in Phase 2 Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
Telix Pharmaceuticals Limited recently announced the first patient has been dosed in a Phase 2 trial exploring the clinical utility of Telix’s first-in-class investigational PET1…
Bora Appoints First Division President of its CDMO Business
Bora Pharmaceuticals Co., Ltd. recently announced the appointment of J.D. Mowery to the newly created position of Division President of Bora’s CDMO business. “Through our…
DRUG DELIVERY - Advancements in Transdermal Delivery Systems: A Focus on Invisicare® Technology for Obesity Treatment
James A. Roszell, PhD, and Doreen McMorran demonstrate how this technology has demonstrated potential in the transdermal administration of glucagon-like peptide-1 (GLP-1) agonists and cannabinoid receptor type 1 (CB-1) antagonists, primarily targeting obesity management and other conditions requiring glucose regulation.
FORMULATION FORUM - Lyophilization Technology - An Enabler for Stable Formulations of Small & Large Molecules
Shaukat Ali, PhD, and Jim Huang, PhD, explain how lyophilization or freeze-drying technology is one of the ideal methods that leads to immobilization of drug and other components that remain in solid or powder state for extended periods without concerns of degradation, and how it has also been applied to improve drug solubility by means of amorphous solid dispersions.
EVerZom Achieves First Bioproduction of Clinical-Grade Stem Cell-Derived Exosomes in Large-Scale Bioreactors
EVerZom recently announced it has reached a key milestone in its development with the production of a first exosome GMP batch in a 10L bioreactor…
THERAPEUTIC FOCUS - Pushing Boundaries in Idiopathic Pulmonary Fibrosis Clinical Research
Laura Iliescu, MSc, and Justin Herman, MD, explore the changing landscape of IPF and how biopharmaceutical companies developing novel treatments can effectively navigate the emerging challenges in a rapidly evolving IPF landscape.
CONTROLLED RELEASE - How Advanced Excipient Knowledge is Shaping the Future of Controlled-Release Formulations
Matthias Knarr, PhD, and True Rogers, PhD, review the latest insights behind CR formulations using HPMC excipients and how HPMC substitution specifically can assist formulators in developing cutting-edge CR delivery systems with differentiated performance.
EXECUTIVE INTERVIEW - Respiratory Drug Development: Lonza Experts Share Trends & Key Takeaways
Beatriz Fernandes, Principal Scientist for R&D, and Kim Shepard, Director, Technology Head Respiratory Delivery, at Lonza, discuss their presentations at RDD 2024, current trends, and the future of the inhalation space.
TOPICAL DELIVERY - Direct Effects™ Perampanel (FYCOMPA®): First Topical Anticonvulsant to Treat Seizures, Headache & Other Symptoms in Epilepsy
Ronald Aung-Din, MD, Sasha Feygin, and Daniele La Rosa say Direct Effects topical perampanel is effective in treating headache and other neurological symptoms commonly encountered in patients with seizures and other conditions in which neuronal instability and hyper-excitability exist.
Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) From Roche
Lonza recently announced it has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, CA, from Roche for $1.2 billion. The Vacaville…
